TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16344320
Drug: FDR gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDR gemcitabine 1,000 mg/m2 at 10 mg/m2/min with cisplatin 20 mg/m2 on days 1 and 8 of a 21-day cycle
Study: 10800798
Drug: heparin-coated circuit
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin-coated circuit with aprotinin (HCO-A)
Study: 10800798
Drug: heparin-coated circuit
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin-coated circuit without aprotinin (HCO)
Study: 18672641
Drug: Quinaril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinaril (20 mg quinapril hydrochloride)
Study: 16091254
Drug: Immune-based therapies
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune-based therapies as an adjunct to antiretroviral treatment
Study: 16091254
Drug: Immune-based therapies
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune-based therapies
Study: 16091254
Drug: Immunomodulating therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulating therapies
Study: 10575530
Drug: Reteplase (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reteplase (administered in bolus injections)
Study: 7677218
Drug: Paromomycin ointment
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paromomycin ointment applied twice a day from day 1 through day 14
Study: 7677218
Drug: Paromomycin ointment
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paromomycin ointment
Study: 7677218
Drug: Paromomycin ointment
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paromomycin ointment and Placebo
Study: 382379
Drug: Antibiotics +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics + Placebo
Study: 382379
Drug: Antibiotics +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics + Pseudoephedrine
Study: 382379
Drug: Antibiotics +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics + Triprolidine
Study: 31821157
Drug: β-hydroxybutyrate infusion
Normalized name: 4-hydroxybutyric acid
DrugBank: gamma-Hydroxybutyric acid (DB01440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-hydroxybutyrate infusion
Study: 30420448
Drug: Ipilimumab 10
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 10 mg/kg + High-Dose Interferon-α2b (HDI)
Study: 23478743
Drug: Aliskiren (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (150 mg daily, increased to 300 mg as tolerated)
Study: 18355658
Drug: Amlodipine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine treatment
Study: 16736344
Drug: Aprotinin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (1 x 10(6) KIU loading dose before surgery and 5 x 10(5) KIU/h during surgery, gross dose: 2.5 x 10(6) KIU, n=36)
Study: 16736344
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (control, n=40)
Study: 27138794
Drug: Raloxifene (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (120 mg per day orally)
Study: 1959195
Drug: Nisoldipine 10
Normalized name: nisoldipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 10 mg twice daily
Study: 6337605
Drug: Dazoxiben (thromboxane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dazoxiben (thromboxane synthetase inhibitor)
Study: 31911146
Drug: Double-dose inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose inactivated influenza vaccine
Study: 26269098
Drug: AVATAR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVATAR therapy (7 sessions)
Study: 21974746
Drug: Six weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Six weekly sessions of motivational interviewing and cognitive behavioral therapy initiated approximately six weeks prior to release from prison.
Study: 19303683
Drug: Continuous increase
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous increase in uric acid levels (1 mg/dL)
Study: 12031560
Drug: 50-microg misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50-microg misoprostol tablet placed in the posterior vaginal fornix
Study: 9440664
Drug: Glyburide 20
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide 20 mg
Study: 2775607
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg DUP 996
Study: 361155
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg eight-hourly plus phentolamine 20 mg three-hourly by mouth for three weeks
Study: 27633773
Drug: Manipulated morphine-ADER-IMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulated morphine-ADER-IMT (60 mg, manipulated)
Study: 27633773
Drug: Intact morphine-ADER-IMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact morphine-ADER-IMT (60 mg, intact)
Study: 24910102
Drug: Ketamine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.3 mg/kg
Study: 8092501
Drug: Morphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.1 mg/kg
Study: 23096008
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg L-theanine via capsules
Study: 23096008
Drug: L-theanine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-theanine (both treatments)
Study: 19735580
Drug: hLF1-11 (0.005,
Approvals — FDA: no, EMA: no, PMDA: no
Description: hLF1-11 (0.005, 0.05, 0.5, 5 mg single and multiple intravenous doses)
Study: 19735580
Drug: hLF1-11 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: hLF1-11 (5 mg single intravenous dose)
Study: 3428343
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml saline in the lumbar epidural interspace (n = 5)
Study: 3428343
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml saline in the thoracic epidural interspace (n = 5)
Study: 27798211
Drug: Atazanavir/cobicistat (300/150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/cobicistat (300/150 mg) + daclatasvir (30 mg) once daily
Study: 27798211
Drug: Atazanavir/ritonavir (300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir (300/100 mg) + daclatasvir (30 mg) once daily
Study: 26637210
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of mycophenolate mofetil (MMF) - 1.03 ± 0.19 g/day at 1 week
Study: 21503807
Drug: Acetaminophen (APAP)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (APAP) 975 mg
Study: 17036476
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of nylestriol for 3 months, 2 mg each time, twice each month; medroxyprogesterone added from the third month for 7 days, 6 mg each day.
Study: 1304807
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg chloral hydrate with 25 mg hydroxyzine
Study: 1304807
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg temazepam
Study: 24776754
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) dosed per m2 BSA
Study: 24776754
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) dosed per kg BW
Study: 23169946
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens alone (0.625 mg/d)
Study: 20130951
Drug: Cefepime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (2 g x 2/day)
Study: 13680555
Drug: β-blockade treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blockade treatment
Study: 1427414
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg aspirin/day
Study: 28328548
Drug: TDF/FTC (once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF/FTC (once-weekly directly observed therapy)
Study: 23085738
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg loading dose (LD) followed by 10 mg maintenance dose (MD) for 10 days
Study: 25286173
Drug: β-lactam monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-lactam monotherapy
Study: 21395645
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ABZ
Study: 21395645
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ABZ + 1500 mg PZQ
Study: 15565824
Drug: EC plus
Normalized name: Ivomec Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC plus filgrastim (480 microg or 300 microg daily or every other day, on day 8 through day 14, and 300 microg daily on days 8 and 12 of each chemotherapy course)
Study: 10655529
Drug: Rice flour
Normalized name: Rice Flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice flour (50 g per liter of oral rehydration solution)
Study: 10655529
Drug: High-amylose maize
Normalized name: hydroxypropyl distarch phosphate, high amylose corn
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-amylose maize starch (50 g per liter of oral rehydration solution)
Study: 31806540
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg olaparib twice daily
Study: 31806540
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg olaparib twice daily
Study: 31806540
Drug: Olaparib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (both doses)
Study: 18082500
Drug: Low-dose MCC-135
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose MCC-135
Study: 18082500
Drug: High-dose MCC-135
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose MCC-135
Study: 12742838
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution (saline placebo)
Study: 11044264
Drug: Micronutrient supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient supplementation with SP treatment
Study: 11044264
Drug: Micronutrient supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient supplementation without SP treatment
Study: 6539224
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg codeine phosphate
Study: 1576052
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg propantheline bromide
Study: 1576052
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metoclopramide monohydrochloride
Study: 21672343
Drug: Palonosetron 0.075
Normalized name: palonosetron 0.075 MG in 1.5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.075 mg
Study: 23431958
Drug: Oral ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ivermectin 200 µg/kg body weight
Study: 12577414
Drug: RT-GSP (Radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT-GSP (Radiotherapy combined with Ginseng polysaccharide injection)
Study: 26336957
Drug: ezetimibe/simvastatin (10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin (10/20 mg)
Study: 26336957
Drug: atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin (10 mg, 20 mg)
Study: 12882653
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor (PI) therapy
Study: 1466216
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of parenteral morphine
Study: 28007025
Drug: XELIRI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELIRI with or without bevacizumab (7.5 mg/kg on day 1), repeated every 3 weeks
Study: 28007025
Drug: FOLFIRI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI with or without bevacizumab (5 mg/kg on day 1), repeated every 2 weeks
Study: 21444695
Drug: Daptomycin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin (8 mg/kg of body weight)
Study: 21444695
Drug: Control subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control subjects (standard-of-care antibiotic)
Study: 8543957
Drug: L-tryptophan
Normalized name: L-tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-tryptophan
Study: 10199444
Drug: Tropisetron 5
Normalized name: tropisetron 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 5 mg intravenously followed by oral therapy for 5 days
Study: 10199444
Drug: Tropisetron 5
Normalized name: tropisetron 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 5 mg intravenously plus dexamethasone before cisplatin and twice daily thereafter
Study: 10199444
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide (2 mg/kg) combined with clemastine, dexamethasone, and lorazepam
Study: 10199444
Drug: Tropisetron 5
Normalized name: tropisetron 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 5 mg intravenously plus dexamethasone
Study: 8849290
Drug: Inpatient chemotherapy
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient chemotherapy (5-FU + CDDP)
Study: 8849290
Drug: Oral UFT
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral UFT (400-600 mg/day) after chemotherapy
Study: 1980218
Drug: Flumazenil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (10 ml, 0.1 mg/ml)
Study: 1980218
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 ml vehicle alone)
Study: 27523491
Drug: Ranibizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.5 mg/0.05 mL)
Study: 28335413
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (PG) - 20 mg placebo with half-dose antibiotics
Study: 17766659
Drug: Pegaspargase (Oncaspar)
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegaspargase (Oncaspar) at a dose of 2,500 IU/m(2) administered i.m. on day 3 of the 4-week induction phase and on day 3 of each of two 8-week delayed intensification phases
Study: 17766659
Drug: Native Escherichia
Normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native Escherichia coli asparaginase (Elspar) at a dose of 6,000 IU/m(2) administered i.m. three times weekly for nine doses during induction and for six doses during each delayed intensification phase
Study: 9635312
Drug: Bur preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bur preparation with a 1/4-round bur in a low-speed handpiece and acid etching
Study: 9635312
Drug: Conventional preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional preparation (pumicing and acid etching with 37% phosphoric acid)
Study: 3123539
Drug: Oral cromolyn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cromolyn sodium (up to 40 mg/kg/day for 1 week)
Study: 31264770
Drug: Unilateral strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral strength training with mirror therapy (MST)
Study: 27914243
Drug: Bevacizumab-containing neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab-containing neoadjuvant therapy (BCP)
Study: 24013512
Drug: 5 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 × 5 Gy irradiation followed by oxaliplatin-based chemotherapy
Study: 2642790
Drug: Systemic antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotic treatment combined with topical application of antibiotics in the wound at the time of wound closure
Study: 50611
Drug: SCHEDULE A
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCHEDULE A (control): conventional one treatment per day regimen totalling 3,760 rads in 22‐23 days
Study: 9601228
Drug: Myofunctional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofunctional therapy
Study: 27913971
Drug: Placebo myofunctional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo myofunctional therapy
Study: 16604967
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of contrast material (300 mgI/ml) only
Study: 16604967
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of contrast material (350 mgI/ml) only
Study: 25150116
Drug: Blueberry powder
Normalized name: Amino Acids/Biotin/Blueberry Powder Extract/Boron/Calcium/Cholecalciferol/Cyanocobalamin/Folic Acid/Magnesium/Pyridoxine 280 MCG-25 MG-500 MG-300 IU-125 MCG-1 MG-50 MG-10 MG Oral Tablet, Chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blueberry powder (BB), equivalent to 250 g berries daily for 6 weeks
Study: 17305635
Drug: Topical cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporin
Study: 10901509
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg daily)
Study: 9809932
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) (0.625 mg of conjugated estrogen and 2.5 mg of medroxyprogesterone acetate daily)
Study: 9809932
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HRT and Simvastatin
Study: 8689742
Drug: Open flap/expanded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open flap/expanded polytetrafluoroethylene (e‐PTFE) membrane combination therapy
Study: 8689742
Drug: Open flap
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open flap therapy alone
Study: 23997371
Drug: Eszopiclone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eszopiclone (3 mg)
Study: 16936810
Drug: 30% iron-saturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% iron-saturated bovine lactoferrin (bLf) (100 mg twice a day)
Study: 16936810
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (pregnant women refusing treatment)
Study: 23977198
Drug: DEP-CAF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEP-CAF (5 mg.kg(‐1) of caffeine intake 1 hour before the trial)
Study: 17254579
Drug: Gonadotropin in
Normalized name: Choriogonadotropin intact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin in combination with metformin
Study: 7957534
Drug: Hydrocortisone (HC)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HC) 100 mg
Study: 7957534
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) 40 mg
Study: 7957534
Drug: Hydrocortisone (HC)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HC) 400 mg
Study: 7957534
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) 80 mg
Study: 28099755
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (human NPH insulin/human regular insulin)
Study: 25956891
Drug: Valacyclovir (VACV)
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valacyclovir (VACV) 2 g thrice daily for 90 days (n = 40)
Study: 335789
Drug: Chlorpromazine (CPZ)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine (CPZ) 600 mg per day
Study: 8951686
Drug: Cysteamine drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteamine drops (0.5% and 1.0%) administered preoperatively every half hour for two, four, six or eight hours
Study: 1348805
Drug: Injection treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection treatment
Study: 3908121
Drug: Labetalol 200-400
Normalized name: labetalol hydrochloride 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 200-400 mg twice daily
Study: 3908121
Drug: Nifedipine and
Normalized name: nifedipine and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine and Labetalol in combination
Study: 3908121
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Nifedipine and Labetalol)
Study: 3908121
Drug: Labetalol alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol alone and in combination with Nifedipine
Study: 19853687
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral anticoagulation therapy and clopidogrel 75 mg/d
Study: 19853687
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (clopidogrel + oral anticoagulants + aspirin)
Study: 11482539
Drug: Prescription of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of multivitamins
Study: 8227938
Drug: Spray to
Normalized name: DERMUSPRAY TOP AEROSOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray to eyes that were open
Study: 27852348
Drug: Guided Self-Help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided Self-Help Cognitive Behavior Therapy (cGSH)
Study: 10955773
Drug: 4‐HPR (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐HPR (200 mg once daily)
Study: 8694306
Drug: Remifentanil small
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil small dose (0.5 micrograms.kg‐1.min‐1)